FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200465068> ?p ?o ?g. }

• W4200465068 endingPage "684" @default.
• W4200465068 startingPage "684" @default.
• W4200465068 abstract "Abstract Relapsed/refractory diffuse large B-cell lymphomas (r/r-DLBCL) are a therapeutic challenge, especially in patients not suitable for high dose chemotherapy, stem cell transplantation or patients who fail CAR-T-cell therapy. r/r-DLBCLs are highly heterogeneous both clinically and molecularly, which imposes a pressing need to develop novel therapies to improve outcomes in patients independently of the molecular subtype. We describe here BTM-3566, a first-in-class compound with activity against a variety of B-cell malignancies but with greatest effect in DLBCL. BTM-3566 activates the mitochondrial integrated stress response (ISR) through a novel mechanism regulated by the mitochondrial protein FAM210B. BTM-3566 induces apoptosis in DLBCL lines in vitro and complete tumor regression in vivo in DLBCL PDX mouse models harboring genetic alterations associated with poor prognosis. BTM-3566 is an oral small molecule based on a pyrazolothiazol-backbone, developed for treatment of diffuse large B-cell lymphoma (DLBCL). BTM-3566 induces apoptosis and complete cell killing in DLBCL lines a with an IC 50 of ~200 - 500 nM. Responsive DLBCL cell lines include ABC, GCB, and double-hit and triple-hit lymphoma lines. Pharmacokinetic studies in mice showed suitability for once daily dosing, with &gt; 50% of oral bioavailability and close to 6 hours of serum half-life. 14-day dosing in mice and dogs demonstrated excellent tolerability at therapeutic doses. BTM-3566 showed stability in human hepatocytes (IC &lt; 5 ml/min*kg) as well and a favorable in vitro safety profile. In xenograft models using the double-hit DLBCL line SU-DHL-10, BTM-3566 treatment resulted in complete regression in all tumor-bearing animals. Most importantly, no subsequent tumor growth occurred for 2 weeks after cessation of therapy, indicating that treatment with BTM-3566 resulted in a durable complete remission in this model of double-hit DLBCL. Expansion studies into human DLBCL PDX models harboring a range of high-risk genomic alterations, including Myd88 mutations and MYC and BCL2 rearrangements, demonstrated response in 100% of the lines with complete tumor regression in 6 of 8 PDX models tested (Table 1). Transcriptome and proteome analyses revealed that BTM-3566 strongly activated the ATF4-integrated stress response (ISR), indicated by phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) and subsequent upregulation of the transcription factor ATF4. Of the four eIF2a-kinases in the human genome we determined, using CRISPR-Cas 9 gene depletion, that HRI was uniquely required for BTM-3566 eIF2a phosphorylation, induction of ATF4 ISR and apoptosis. HRI is described as being activated by mitochondrial-related stress, including heme depletion, increased ROS generation or blockage of mitochondrial ATP synthesis which result in an increase in mitochondrial proteostasis including activation of mitochondrial protease OMA1. We determined that BTM-3566 activates OMA1 without acting as a classical mitochondrial toxin. Treatment with BTM-3566 induced OMA1-dependent OPA1 processing and mitochondrial fragmentation in as little as 30 minutes of treatment, in the absence of any reduction in mitochondrial oxygen consumption or membrane depolarization. This data indicates that BTM-3566 represents a new class of compounds that activate the mitochondrial protease OMA1. Gene expression-based profiling of BTM-3566 sensitivity in over 400 cancer cell lines showed that FAM210B, a mitochondrial membrane protein, negatively correlated with response to BTM-3566. Notably, overexpression of FAM210B completely prevents OMA1 activation and causes complete resistance to BTM-3566-induced apoptosis in DLBCL cell line BJAB and the Burkitt lymphoma cell line Ramos. Thus, FAM210B serves as a strong predictor of BTM-3566 sensitivity, as well as revealing a novel mechanism of regulation of OMA1 activation. In summary, we describe here a novel, highly potent activator of the mitochondrial ISR, which is well tolerated in mice and dogs, has favorable pharmacokinetics and induces robust DLBCL regression in-vivo. An IND application in B-cell malignancies will be completed by early Q1 2022 with initiation of first in human clinical trials the first half of 2022. Figure 1 Figure 1. Disclosures Schwarzer: Bantam Pharmaceutical: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Anantha: Bantam Pharmaceutical: Consultancy, Current Employment, Current holder of stock options in a privately-held company. Cooper: Bantam Pharmaceutical: Consultancy. Hannink: Bantam Pharmaceutical: Research Funding. Hembrough: Bantam Pharmaceutical: Consultancy. Levine: Bantam Pharmaceutical: Consultancy, Current holder of individual stocks in a privately-held company. Luther: Bantam Pharmaceutical: Current holder of individual stocks in a privately-held company, Ended employment in the past 24 months, Membership on an entity's Board of Directors or advisory committees. Stocum: Bantam Pharmaceutical: Current Employment, Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees. Liesa-Roig: Bantam Pharmaceutical: Research Funding. Kostura: Bantam Pharmaceutical: Consultancy, Current holder of stock options in a privately-held company, Patents & Royalties: Named Inventor on patents with assignment to Bantam Pharmaceutical." @default.
• W4200465068 created "2021-12-31" @default.
• W4200465068 creator A5009891360 @default.
• W4200465068 creator A5032103167 @default.
• W4200465068 creator A5034569614 @default.
• W4200465068 creator A5038429210 @default.
• W4200465068 creator A5041468323 @default.
• W4200465068 creator A5045522995 @default.
• W4200465068 creator A5045565087 @default.
• W4200465068 creator A5059744648 @default.
• W4200465068 creator A5063442683 @default.
• W4200465068 creator A5064715897 @default.
• W4200465068 creator A5071959357 @default.
• W4200465068 creator A5080562599 @default.
• W4200465068 date "2021-11-05" @default.
• W4200465068 modified "2023-09-27" @default.
• W4200465068 title "Btm-3566, a Novel Activator of the Mitochondrial Stress Response Promotes Robust Therapeutic Responses in Vitro and In Vivo in Diffuse Large B-Cell Lymphoma" @default.
• W4200465068 doi "https://doi.org/10.1182/blood-2021-145637" @default.
• W4200465068 hasPublicationYear "2021" @default.
• W4200465068 type Work @default.
• W4200465068 citedByCount "0" @default.
• W4200465068 crossrefType "journal-article" @default.
• W4200465068 hasAuthorship W4200465068A5009891360 @default.
• W4200465068 hasAuthorship W4200465068A5032103167 @default.
• W4200465068 hasAuthorship W4200465068A5034569614 @default.
• W4200465068 hasAuthorship W4200465068A5038429210 @default.
• W4200465068 hasAuthorship W4200465068A5041468323 @default.
• W4200465068 hasAuthorship W4200465068A5045522995 @default.
• W4200465068 hasAuthorship W4200465068A5045565087 @default.
• W4200465068 hasAuthorship W4200465068A5059744648 @default.
• W4200465068 hasAuthorship W4200465068A5063442683 @default.
• W4200465068 hasAuthorship W4200465068A5064715897 @default.
• W4200465068 hasAuthorship W4200465068A5071959357 @default.
• W4200465068 hasAuthorship W4200465068A5080562599 @default.
• W4200465068 hasBestOaLocation W42004650681 @default.
• W4200465068 hasConcept C150903083 @default.
• W4200465068 hasConcept C190283241 @default.
• W4200465068 hasConcept C203014093 @default.
• W4200465068 hasConcept C207001950 @default.
• W4200465068 hasConcept C2778559949 @default.
• W4200465068 hasConcept C2779338263 @default.
• W4200465068 hasConcept C502942594 @default.
• W4200465068 hasConcept C54355233 @default.
• W4200465068 hasConcept C55493867 @default.
• W4200465068 hasConcept C71924100 @default.
• W4200465068 hasConcept C81885089 @default.
• W4200465068 hasConcept C86803240 @default.
• W4200465068 hasConcept C98274493 @default.
• W4200465068 hasConceptScore W4200465068C150903083 @default.
• W4200465068 hasConceptScore W4200465068C190283241 @default.
• W4200465068 hasConceptScore W4200465068C203014093 @default.
• W4200465068 hasConceptScore W4200465068C207001950 @default.
• W4200465068 hasConceptScore W4200465068C2778559949 @default.
• W4200465068 hasConceptScore W4200465068C2779338263 @default.
• W4200465068 hasConceptScore W4200465068C502942594 @default.
• W4200465068 hasConceptScore W4200465068C54355233 @default.
• W4200465068 hasConceptScore W4200465068C55493867 @default.
• W4200465068 hasConceptScore W4200465068C71924100 @default.
• W4200465068 hasConceptScore W4200465068C81885089 @default.
• W4200465068 hasConceptScore W4200465068C86803240 @default.
• W4200465068 hasConceptScore W4200465068C98274493 @default.
• W4200465068 hasIssue "Supplement 1" @default.
• W4200465068 hasLocation W42004650681 @default.
• W4200465068 hasOpenAccess W4200465068 @default.
• W4200465068 hasPrimaryLocation W42004650681 @default.
• W4200465068 hasRelatedWork W1563073167 @default.
• W4200465068 hasRelatedWork W2026185605 @default.
• W4200465068 hasRelatedWork W2056936324 @default.
• W4200465068 hasRelatedWork W2098045335 @default.
• W4200465068 hasRelatedWork W2393123779 @default.
• W4200465068 hasRelatedWork W2886448606 @default.
• W4200465068 hasRelatedWork W2979882259 @default.
• W4200465068 hasRelatedWork W3001698141 @default.
• W4200465068 hasRelatedWork W3008207576 @default.
• W4200465068 hasRelatedWork W3215795316 @default.
• W4200465068 hasVolume "138" @default.
• W4200465068 isParatext "false" @default.
• W4200465068 isRetracted "false" @default.
• W4200465068 workType "article" @default.